Disaccharidase Activity Panel
Test in Focus
Mayo Clinic Labs’ new disaccharidase activity panel measures levels of five naturally occurring digestive enzymes to detect deficiencies that affect carbohydrate absorption. The panel, as explained by Mayo Clinic pediatric gastroenterologist Pua Hopson, D.O., in this episode of the "Answers From the Lab" podcast, is the gold standard for diagnosing disaccharidase deficiencies, which can cause chronic conditions like celiac disease.
“Oftentimes when we see these patients who have had chronic illness and have chronic symptoms going on for such a long time, it’s hard to piece together the history,” says Dr. Hopson. “It can be quite complex to tease out ‘A causes B.’ In doing an endoscopy the addition of this test may be really beneficial if you find a deficiency, and sometimes can provide a lot of clarity for your patients’ symptoms.”
Dr. Hopson explains that in the proper clinical setting, disaccharidase activity testing can increase disaccharidase disorder identification by 10% to 20%. “In these cases, you’ll have a higher chance of detecting abnormalities and overall helping your patients clinically.”
Listen to learn more about how disaccharidase activity testing improves patient outcomes by equipping providers with specific details about patients’ malabsorption disorders to confirm diagnosis and inform treatment choices.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluation of patients who present with signs or symptoms suggestive of disaccharidase disorders. This test is not intended for carrier detection.
Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.